QNRX Overview

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Wall Street analysts forecast QNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNRX is70.00 USD with a low forecast of 70.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Quoin Pharmaceuticals Ltd revenue for the last quarter amounts to -4.52M USD, increased 87.96

Quoin Pharmaceuticals Ltd. EPS for the last quarter amounts to -5035025.00 USD, increased 125.13

Quoin Pharmaceuticals Ltd (QNRX) has 4 emplpoyees as of May 07 2026.

Today QNRX has the market capitalization of 11.60M USD.